Opening Bell Analysts Research Calls for Thursday, March 16

This report was sent to Briefing.com subscribers earlier today. 

Research calls posted earlier this morning are available here. 

Upgrades:

> Alamo Group (ALG) upgraded to Buy from Neutral at DA Davidson; tgt raised to $196

> Block (SQ) upgraded to Buy from Neutral at Mizuho; tgt raised to $93

> Deutsche Boerse (DBOEY) upgraded to Outperform from Neutral at Credit Suisse

> HF Sinclair (DINO) upgraded to Overweight from Equal Weight at Wells Fargo; tgt $55

> LexinFintech (LX) upgraded to Buy from Accumulate at CLSA; tgt $3.45

> On (ONON) upgraded to Outperform from Neutral at Wedbush; tgt raised to $25

> Progressive (PGR) upgraded to Overweight from Underweight at Wells Fargo; tgt raised to $158

> TPI Composites (TPIC) upgraded to Buy from Neutral at Guggenheim; tgt $22

> UiPath (PATH) upgraded to Buy from Hold at Canaccord Genuity; tgt raised to $19

> Under Armour (UAA) upgraded to Buy from Hold at Williams Trading; tgt $11

Downgrades:

> Halozyme Therapeutics (HALO) downgraded to Market Perform from Outperform at SVB Securities; tgt $42

> Kezar Life Sciences (KZR) downgraded to Mkt Perform from Outperform at William Blair

> LivePerson (LPSN) downgraded to Hold from Buy at Craig Hallum; tgt lowered to $6

> Man Group (MNGPF) downgraded to Neutral from Outperform at Exane BNP Paribas

> Millicom International Cellular (TIGO) downgraded to Neutral from Overweight at JP Morgan

> Mytheresa (MYTE) downgraded to Market Perform from Outperform at TD Cowen; tgt lowered to $7

> Olaplex (OLPX) downgraded to Market Perform from Outperform at TD Cowen; tgt lowered to $4.50

Others:

> Cerevel Therapeutics (CERE) resumed with a Hold at Berenberg; tgt $22

> Inc. (EHAB) initiated with a Neutral at Goldman; tgt $15

> Global Net Lease (GNL) initiated with an Underperform at Exane BNP Paribas; tgt $13

> Intuit (INTU) initiated with a Neutral at UBS; tgt $430

> Safehold (SAFE) initiated with an Outperform at Exane BNP Paribas

> Samsara (IOT) initiated with a Neutral at Piper Sandler; tgt $21

> StoneCo (STNE) removed from Tactical Outperform List at Evercore ISI

> Theseus Pharmaceuticals (THRX) initiated with a Buy at Stifel; tgt $24